导师风采
孙永琨
个人信息
Personal Information
- 性别：男
- 导师类型：博士生导师
- 职称：主任医师
- 该职称任职时间：20200930
联系方式
Contact Information
- 所属院系：肿瘤医院
- 所属专业：
- 邮箱 : hsunyk@126.com
- 工作电话 : 87788800
个人简介
Personal Profile
2005年至今一直在中国医学科学院肿瘤医院内科工作，从住院医师开始，逐步成长为主任医师。熟悉常见恶性肿瘤的诊疗原则和内科治疗方法，特别是消化系统恶性肿瘤、泌尿系统肿瘤以及男性生殖系统肿瘤的诊疗规范和研究进展，在实践中强调循证医学和个体化治疗相结合。能综合应用化疗药物、靶向治疗、免疫治疗和生物治疗等多种治疗手段，为患者带来生存获益和生活质量改善。
团队简介
Team Profile
待补充更新
- 研究方向Research Directions
肿瘤内科治疗,新药临床研发,肿瘤发生与耐药
- 在校研究生Current Graduate Students
硕士研究生 2 名，博士研究生 1 名
- 科研项目Research Projects
| # | 项目名称 | 起止日期 | 金额 | 项目类型 | 本人角色 |
|---|---|---|---|---|---|
| 1 | 去泛素化酶USP39调 控RNA剪接驱动食管 癌发生的新机制 | 2021-01 —— 2024-12 | 55万元 | 主持在研的国家或省部级科研项目 | 主持人 |
| 2 | 伊立替康及曲氟尿苷替匹嘧啶联合贝伐珠单抗二线治疗mCRC的I/II期临床研究 | 2022-10 —— 2025-09 | 10万元 | 主持的企业/行业委托重大项目 | 主持人 |
- 发表论文Papers
| # | 论文题目 | 期刊名称 | 发表年份 | 论文署名 |
|---|---|---|---|---|
| 1 | Identification of the six-hormone secretion-related gene signature as a prognostic biomarker for colon adenocarcinoma | Cancer Biomark | 2023-12 | Xiongjie Jia |
| 2 | FOLFOXIRI plus cetuximab as conversion therapy for unresectable RAS/BRAF wild-type left-sided colorectal cancer with liver-limited metastases: a prospective dual-center pilot study | Frontiers in Oncology | 2024-04 | Wenwei Yang |
| 3 | Case report: Immunotherapy in rare high TMB pancreatic acinar carcinoma | Frontiers in Oncology | 2024-03 | Yuting Fang |
| 4 | 恶性腹膜间皮瘤内科治疗的研究进展 | 中国肿瘤临床与康复 | 2023-08 | Yuting Fang |
| 5 | 靶向免疫联合局部治疗中晚期肝细胞癌中国专家共识 | 肝癌电子杂志 | 2023-09 | Xinyu Bi; Yongkun Sun;Zhengqiang Yang |
| 6 | Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis | HEPATOLOGY | 2023-01 | Jun Zhou; Yongkun Sun |
| 7 | Recent advances in targeted therapy for pancreatic adenocarcinoma | World Journal of Gastrointestinal Oncology | 2023-04 | Yuting Fang |
| 8 | Comparison of clinicopathological characteristics and survival outcomes between gallbladder mucinous adeandnocarcinoma gallbladder adenocarcinoma: A propensity score-matched study | World Journal of Gastrointestinal Oncology | 2023-08 | Wenwei Yang |
| 9 | Current neoadjuvant therapy for operable locally advanced esophageal cancer | MEDICAL ONCOLOGY | 2023-07 | Wenwei Yang |
| 10 | Nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule(S-1)as first-line treatment for advanced biliary tract adenocarcinoma: a phase 2 clinical trial | Hepatobiliary Surgery and Nutrition | 2023-02 | Wen Zhang; Yongkun Sun |
| 11 | Intracellular and extracellular factors of colorectal cancer liver metastasis: a pivotal perplex to be fully elucidated | Cancer Cell International | 2022-11 | Yaru Niu |
| 12 | 转移性结直肠癌三线治疗的研究现状及进展 | 中华结直肠疾病电子杂志 | 2022-10 | Wenwei Yang |
| 13 | Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statement | Liver Cancer | 2022-06 | Yongkun Sun |
| 14 | A predictive model for early death in elderly patients with gastric cancer: A population-based study. | Frontiers in Oncology | 2022-08 | Wenwei Yang |
| 15 | Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview | 0ncoTargets and Therapy | 2021-02 | Wenwei Yang |
| 16 | Long-term survival of a patient with pancreatic cancer and lung metastasis: A case report and review of literature | World Journal of Clinical Cases | 2021-10 | Wenwei Yang |
| 17 | The Deubiquiti.nase USP39 Promotes EsophagealSquamous Ce11 Carcinoma Maligrancy as a Splicing Factor | Genes | 2022-05 | Xiaolin Zhu |
| 18 | 安罗替尼治疗复发难治型晚期结直肠癌III期临床研究的单中心数据分析 | 中国肿瘤临床 | 2022-02 | Wenwei Yang |
| 19 | Anlotinib in the treatment of advanced hepatocellular carcinoma:an open - label phase Il study (ALTER -0802 study) | Hepatology International | 2021-06 | Yongkun Sun |
| 20 | Phase I dose-escalation study of chiauranib, a novel angioge.nic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors | Journal of Hematology Oncology | 2019-01 | Yongkun Sun |
| 21 | 雷替曲塞联合伊立替康治疗晚期结直肠癌的临床观察 | 中华结直肠疾病电子杂志 | 2020-08 | Yujie Ma |
| 22 | 从三药化疗到靶向免疫联合治疗结肠癌肝转移1例报告及文献复习 | 肝癌电子杂志 | 2020-09 | Donghui Wang |
| 23 | 伊立替康联合卡培他滨或替吉奥二线治疗晚期结直肠癌效果观察 | 肿瘤研究与临床 | 2019-06 | Yujie Ma |
- 科研获奖Research Awards
无
- 研究成果Research Findings
无